全文获取类型
收费全文 | 25605篇 |
免费 | 1333篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 131篇 |
儿科学 | 431篇 |
妇产科学 | 317篇 |
基础医学 | 3396篇 |
口腔科学 | 739篇 |
临床医学 | 1720篇 |
内科学 | 5980篇 |
皮肤病学 | 479篇 |
神经病学 | 2478篇 |
特种医学 | 1143篇 |
外科学 | 4423篇 |
综合类 | 104篇 |
现状与发展 | 1篇 |
预防医学 | 846篇 |
眼科学 | 609篇 |
药学 | 1973篇 |
中国医学 | 62篇 |
肿瘤学 | 2223篇 |
出版年
2023年 | 136篇 |
2022年 | 290篇 |
2021年 | 535篇 |
2020年 | 257篇 |
2019年 | 379篇 |
2018年 | 504篇 |
2017年 | 397篇 |
2016年 | 465篇 |
2015年 | 474篇 |
2014年 | 626篇 |
2013年 | 794篇 |
2012年 | 1268篇 |
2011年 | 1459篇 |
2010年 | 770篇 |
2009年 | 638篇 |
2008年 | 1177篇 |
2007年 | 1345篇 |
2006年 | 1352篇 |
2005年 | 1315篇 |
2004年 | 1250篇 |
2003年 | 1198篇 |
2002年 | 1195篇 |
2001年 | 810篇 |
2000年 | 822篇 |
1999年 | 772篇 |
1998年 | 303篇 |
1997年 | 243篇 |
1996年 | 217篇 |
1995年 | 177篇 |
1994年 | 163篇 |
1993年 | 172篇 |
1992年 | 546篇 |
1991年 | 491篇 |
1990年 | 458篇 |
1989年 | 446篇 |
1988年 | 433篇 |
1987年 | 372篇 |
1986年 | 364篇 |
1985年 | 368篇 |
1984年 | 212篇 |
1983年 | 170篇 |
1982年 | 99篇 |
1981年 | 91篇 |
1980年 | 88篇 |
1979年 | 172篇 |
1978年 | 128篇 |
1977年 | 96篇 |
1974年 | 129篇 |
1973年 | 115篇 |
1969年 | 102篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Naoto Jingami Riki Matsumoto Hirotaka Ito Atsushi Ishii Yukiko Ihara Shinichi Hirose Akio Ikeda Ryosuke Takahashi 《Epileptic Disord》2014,16(2):227-231
Generalised (genetic) epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome with various phenotypes. The majority of individuals with GEFS+ have generalised seizure types, in addition to febrile seizures (FS) or febrile seizures plus (FS+), defined as either continued FS after 6 years of age or afebrile seizures following FS. A 27‐year‐old man with no history of FS/FS+ experienced intractable generalised convulsive seizures. The patient's father had a history of similar seizures during puberty and the patient's siblings had only FS. No individual in the family had both generalised seizures and FS/FS+, although GEFS+ might be considered to be present in the family. Analysis of SCN1A, a sodium channel gene, revealed a novel mutation (c.3250A>T [S1084C]) in the cytoplasmic loop 2 of SCN1A in both the patient and his father. Most previously reported SCN1A mutations in GEFS+ patients are located in the conserved homologous domains of SCN1A, whereas mutations in the cytoplasmic loops are very rare. SCN1A gene analysis is not commonly performed in subjects with generalised seizures without FS. SCN1A mutation may be a clinically‐useful genetic marker in order to distinguish GEFS+ patients from those with classic idiopathic generalised epilepsy, even if they present an atypical clinical picture. 相似文献
992.
993.
994.
Mitsuko Nakashima Hirofumi Kashii Yoshiko Murakami Mitsuhiro Kato Yoshinori Tsurusaki Noriko Miyake Masaya Kubota Taroh Kinoshita Hirotomo Saitsu Naomichi Matsumoto 《Neurogenetics》2014,15(3):193-200
Recessive mutations in genes of the glycosylphosphatidylinositol (GPI)-anchor synthesis pathway have been demonstrated as causative of GPI deficiency disorders associated with intellectual disability, seizures, and diverse congenital anomalies. We performed whole exome sequencing in a patient with progressive encephalopathies and multiple dysmorphism with hypophosphatasia and identified novel compound heterozygous mutations, c.250G>T (p. Glu84*) and c.1342C>T (p. Arg488Trp), in PIGT encoding a subunit of the GPI transamidase complex. The surface expression of GPI-anchored proteins (GPI-APs) on patient granulocytes was lower than that of healthy controls. Transfection of the Arg488Trp mutant PIGT construct, but not the Glu84* mutant, into PIGT-deficient cells partially restored the expression of GPI-APs DAF and CD59. These results indicate that PIGT mutations caused neurological impairment and multiple congenital anomalies in this patient. 相似文献
995.
Ryo Wada MD PhD Masaya Shinohara MD PhD Tadashi Fujino MD PhD Shingo Matsumoto MD PhD Shintaro Yao MD PhD Kensuke Yano MD Shintaro Dobashi MD PhD Katsuya Akitsu MD PhD Hideki Koike MD PhD Hiroshi Ohara MD PhD Toshio Kinoshita MD PhD Hitomi Yuzawa MD PhD Rine Nakanishi MD PhD Takanori Ikeda MD PhD 《Pacing and clinical electrophysiology : PACE》2023,46(1):73-83
996.
997.
998.
A. Sakai S. Ikeda N. Okimoto H. Matsumoto K. Teshima Y. Okazaki F. Fukuda S. Arita H. Tsurukami M. Nagashima T. Yoshioka 《Osteoporosis international》2014,25(9):2245-2253
Summary
This multi-center, prospective, open-label, observational study evaluated the effects of once-monthly minodronate (50 mg) on treatment persistence, bone turnover markers, bone mineral density, low back pain, and upper gastrointestinal symptoms in outpatients with osteoporosis previously treated with daily or weekly bisphosphonate products.Introduction
The purposes of this study were to investigate the effects of once-monthly oral minodronate (MIN 50 mg) on bone turnover markers and bone mineral density, low back pain, and upper gastrointestinal symptoms, as well as preference for and treatment persistence of MIN 50 mg among Japanese osteoporosis patients currently treated with daily or weekly bisphosphonates.Methods
Study patients were allocated based on their preference to either the Switch group (patients willing to switch over to MIN 50 mg) or the Continue group (patients wanting to continue their current therapies). Patients’ treatment persistence and satisfaction levels with the therapies were assessed using a self-administered questionnaire. The study endpoints were serum TRACP-5b, serum P1NP, bone mineral density, upper gastrointestinal symptoms, and low back pain.Results
In total, 264 and 133 patients were allocated into the Switch and Continue groups, respectively. Approximately, 65 % of patients were willing to switch to MIN 50 mg, with the predominant reason being “less frequent dosing more convenient.” Treatment persistence was significantly higher in the Switch group (MIN 50 mg) than the Continue group. Almost all patients with abnormal bone metabolism markers demonstrated normalization after switchover. MIN 50 mg alleviated low back pain and upper gastrointestinal symptoms induced by prior bisphosphonate use.Conclusions
MIN 50 mg alleviates low back pain, reduces bone turnover markers and increases bone density, and induces fewer upper gastrointestinal symptoms after switchover from prior bisphosphonate products, and therefore, it may provide patients with a more convenient treatment option and enhance long-term treatment persistence. 相似文献999.
Ryuji Ochiai Yoko Sugiura Yasushi Shioya Kazuhiro Otsuka Yoshihisa Katsuragi Teruto Hashiguchi 《Nutrition Research》2014
Brewed coffee is a widely consumed beverage, and many studies have examined its effects on human health. We investigated the vascular effects of coffee polyphenols (CPPs), hypothesizing that a single ingestion of CPP during glucose loading would improve endothelial function. To test this hypothesis, we conducted a randomized acute clinical intervention study with crossover design and measured reactive hyperemia index (RHI) to assess the acute effects of a 75-g glucose load with CPP in healthy, nondiabetic adult men. Blood glucose and insulin levels were elevated after glucose loading with and without CPP, with no significant differences between treatments. The RHI did not significantly decrease after glucose loading without CPP. With CPP, however, RHI significantly (P < .05) increased over baseline after glucose loading. The difference between treatments was statistically significant (P < .05). No significant changes were observed in an oxidative stress marker after glucose loading with or without CPP. These findings suggest that a single ingestion of CPP improves peripheral endothelial function after glucose loading in healthy subjects. 相似文献
1000.
Nobuhiko Tachibana Yoko Yamashita Mayuko Nagata Satoshi Wanezaki Hitoshi Ashida Fumihiko Horio Mitsutaka Kohno 《Nutrition Research》2014
Although the underlying mechanism is unclear, β-conglycinin (βCG), the major component of soy proteins, regulates blood glucose levels. Here, we hypothesized that consumption of βCG would normalize blood glucose levels by ameliorating insulin resistance and stimulating glucose uptake in skeletal muscles. To test our hypothesis, we investigated the antidiabetic action of βCG in spontaneously diabetic Goto-Kakizaki (GK) rats. Our results revealed that plasma adiponectin levels and adiponectin receptor 1 messenger RNA expression in skeletal muscle were higher in βCG-fed rats than in casein-fed rats. Phosphorylation of adenosine monophosphate–activated protein kinase (AMP kinase) but not phosphatidylinositol-3 kinase was activated in βCG-fed GK rats. Subsequently, βCG increased translocation of glucose transporter 4 to the plasma membrane. Unlike the results in skeletal muscle, the increase in adiponectin receptor 1 did not lead to AMP kinase activation in the liver of βCG-fed rats. The down-regulation of sterol regulatory element-binding factor 1, which is induced by low insulin levels, promoted the increase in hepatic insulin receptor substrate 2 expression. Based on these findings, we concluded that consumption of soy βCG improves glucose uptake in skeletal muscle via AMP kinase activation and ameliorates hepatic insulin resistance and that these actions may help normalize blood glucose levels in GK rats. 相似文献